Microbiota, novel antibiotics, and of course drug pricing among #BIO2016 takeaways
Drug pricing was destined to be a major topic, as manufacturers and payers continue to duke it out.
Will CAR-T deliver on the promise of widespread therapeutic improvement?
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BIO 2016: Concussions, Ali, FDA and synthetic biology
Muhammad Ali announced many years ago that he suffered from Parkinson’s disease, but Dr. Bennet Omalu thinks differently, hypothesizing the boxer may have suffered from CTE.
Three big issues in biotech as BIO 2016 gets underway
Don’t worry about it, you’ll sleep next week.
This week on MedHeads: News from #BIO2015 and the Health Innovation Summit
On MedHeads this week, Meghana Keshavan and Neil Versel join Stephanie Baum to discuss important news from the BIO and Health Innovations conferences.